Intercept to Present at Upcoming Conference

NEW YORK, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:

2017 Wedbush PacGrow Healthcare Conference on August 16, 2017 at 9:10 a.m. Eastern Time

Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

CONTACT: 
                    For more information about Intercept Pharmaceuticals, please contact:
                    
                    Intercept Pharmaceuticals:
                    Mark Vignola
                    +1-646-747-1000
                    investors@interceptpharma.com
                    
                    Media inquiries: media@interceptpharma.com
                    
                    Investor inquiries: investors@interceptpharma.com

Distribution channels: Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release